PHAS insider filings
PhaseBio Pharmaceuticals Inc — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-05-19. Screen PHAS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PHAS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — PhaseBio Pharmaceuticals Inc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-05-19 | 4 | van den Broek Richard — Director | Grant/award (A): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Thorp Clay — Director | Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Humphries William D. — Director | Option exercise (M): 2,538 · Option exercise (M): 2,538 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | HARRIGAN EDMUND — Director | Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Sapir Alex — Director | Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Loewy Caroline M — Director | Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Hutson Nancy J — Director | Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2022-10-26 | 4 | NEW ENTERPRISE ASSOCIATES 13 LP — 10% owner NEA Partners 13, Limited Partnership — 10% owner NEA 13 GP, Ltd — 10% owner SANDELL SCOTT D — 10% owner KERINS PATRICK J — 10% owner BASKETT FOREST — 10% owner | Sale (S): 1,784,109 @ $0.15 | EDGAR |
| 2022-06-10 | 4/A | Humphries William D. — Director | Grant/award (A): 11,842 (derivative) @ $0 · Grant/award (A): 2,538 (derivative) @ $0 | EDGAR |
| 2022-05-24 | 4 | Arnold Susan Elizabeth — SVP, Technical Operations | Grant/award (A): 10,917 @ $0.68 | EDGAR |
| 2022-05-24 | 4 | Mow Jonathan P — Chief Executive Officer, Director | Grant/award (A): 10,918 @ $0.68 | EDGAR |
| 2022-05-24 | 4 | Burkhardt Glen — SVP of Human Resources | Grant/award (A): 11,248 @ $0.68 · Sale (S): 11,248 @ $0.79 | EDGAR |
| 2022-05-24 | 4 | Hanson Kristopher — SVP and General Counsel | Grant/award (A): 4,831 @ $0.68 | EDGAR |
| 2022-05-24 | 4 | Birchall Jonathan — Chief Commercial Officer | Grant/award (A): 20,000 @ $0.68 | EDGAR |
| 2022-05-24 | 4 | Sharp John P — Chief Financial Officer | Grant/award (A): 6,026 @ $0.68 | EDGAR |
| 2022-05-20 | 4 | Humphries William D. — Director | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Thorp Clay — Director | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Hutson Nancy J — Director | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Sapir Alex — Director | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Loewy Caroline M — Director | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | HARRIGAN EDMUND — Director | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | van den Broek Richard — Director | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4/A | Hutson Nancy J — Director | Purchase (P): 3,000 @ $3.08 | EDGAR |
| 2022-02-28 | 4 | Burkhardt Glen — VP, Human Resources | Grant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 87,500 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Sharp John P — Chief Financial Officer | Grant/award (A): 24,750 (derivative) @ $0 · Grant/award (A): 115,500 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Birchall Jonathan — Chief Commercial Officer | Grant/award (A): 11,250 (derivative) @ $0 · Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Lee John Sang — Chief Medical Officer | Grant/award (A): 24,750 (derivative) @ $0 · Grant/award (A): 115,500 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Arnold Susan Elizabeth — SVP, Technical Operations | Grant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 87,500 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Hanson Kristopher — VP, Head of Legal | Grant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 87,500 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Mow Jonathan P — Chief Executive Officer, Director | Grant/award (A): 82,500 (derivative) @ $0 · Grant/award (A): 385,000 (derivative) @ $0 | EDGAR |
| 2021-11-23 | 4 | Mow Jonathan P — Chief Executive Officer, Director | Grant/award (A): 5,623 @ $2.01 | EDGAR |
| 2021-11-23 | 4 | Arnold Susan Elizabeth — SVP, Technical Operations | Grant/award (A): 2,559 @ $2.01 | EDGAR |
| 2021-11-23 | 4 | Sharp John P — Chief Financial Officer | Grant/award (A): 2,017 @ $2.01 | EDGAR |
| 2021-11-23 | 4 | Hanson Kristopher — VP, Head of Legal | Grant/award (A): 1,545 @ $2.01 | EDGAR |
| 2021-11-23 | 4 | Burkhardt Glen — VP, Human Resources | Grant/award (A): 5,766 @ $2.01 · Sale (S): 5,766 @ $2.37 | EDGAR |
| 2021-11-09 | 4 | Birchall Jonathan — Chief Commercial Officer | Grant/award (A): 250,000 (derivative) @ $3.37 | EDGAR |
| 2021-11-08 | 4 | Hutson Nancy J — Director | Option exercise (M): 24,860 @ $2.26 · Option exercise (M): 1,500 @ $3.15 · Option exercise (M): 7,400 @ $3.15 · Option exercise (M): 24,860 (derivative) @ $2.26 · Option exercise (M): 1,500 (derivative) @ $3.15 · Option exercise (M): 7,400 (derivative) @ $3.15 | EDGAR |
| 2021-11-03 | 4 | Mow Jonathan P — Chief Executive Officer, Director | Option exercise (M): 20,000 @ $1.24 · Option exercise (M): 20,000 (derivative) @ $1.24 | EDGAR |
| 2021-11-03 | 4 | Sharp John P — Chief Financial Officer | Option exercise (M): 7,500 @ $1.68 · Option exercise (M): 7,500 (derivative) @ $1.68 | EDGAR |
| 2021-09-15 | 4 | Humphries William D. — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4/A | Arnold Susan Elizabeth — VP, Preclinical and Chem | Option exercise (M): 4,519 @ $1.74 · Option exercise (M): 4,519 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4/A | Sharp John P — Chief Financial Officer | Option exercise (M): 7,500 @ $1.68 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2021-08-30 | 4 | Mow Jonathan P — Chief Executive Officer, Director | Option exercise (M): 20,000 @ $1.24 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2021-08-19 | 4 | Hutson Nancy J — Director | Purchase (P): 3,000 @ $3.08 | EDGAR |
| 2021-08-18 | 4 | Thorp Clay — Director | Purchase (P): 10,000 @ $3 | EDGAR |
| 2021-08-04 | 4 | Sharp John P — Chief Financial Officer | Grant/award (A): 7,500 @ $1.68 | EDGAR |
| 2021-07-14 | 4 | Arnold Susan Elizabeth — VP, Preclinical and Chem | Grant/award (A): 4,519 @ $1.74 | EDGAR |
| 2021-06-04 | 4 | Loewy Caroline M — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Hutson Nancy J — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Thorp Clay — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — PhaseBio Pharmaceuticals Inc
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-08-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-12 | 8-K | 1.03 — Bankruptcy or Receivership 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-09-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-25 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PHAS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs